Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

What we know so far

B Gazzard1

  • 1Chelsea and Westminster Hospital, London, UK.

AIDS (London, England)
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Combination antiretroviral therapy offers hope for improved survival in HIV patients. Ongoing research is crucial to determine optimal treatment strategies and long-term outcomes for managing HIV infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The EuroSIDA study: 25 years of scientific achievements.

HIV medicine·2019
Same author

Correction to: CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Journal of neurovirology·2018
Same author

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Journal of neurovirology·2017
Same author

Low levels of neurocognitive impairment detected in screening HIV-infected men who have sex with men: The MSM Neurocog Study.

International journal of STD & AIDS·2016
Same author

Editorial.

HIV medicine·2016
Same author

Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.

PloS one·2015
Same journal

Hazardous alcohol use, sexual behavior, and recent and undiagnosed HIV across 11 Eastern and Southern African countries.

AIDS (London, England)·2026
Same journal

Carotid inflammation on FDG-PET is associated with lower cognitive performance in people with treated HIV infection.

AIDS (London, England)·2026
Same journal

Clinical implications of the new definition of obesity among persons with HIV.

AIDS (London, England)·2026
Same journal

Cabotegravir and rilpivirine resistance-associated mutations among people with newly diagnosed HIV-1 in the Netherlands.

AIDS (London, England)·2026
Same journal

Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.

AIDS (London, England)·2026
Same journal

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Virology
  • Immunology

Background:

  • Combination therapy with zidovudine plus didanosine or zalcitabine demonstrated improved survival and delayed clinical events compared to zidovudine monotherapy.
  • Addition of HIV protease inhibitors to nucleoside analogue combinations shows potential for greater viral load reduction, with early studies indicating clinical benefits and improved survival in advanced HIV infection.

Purpose of the Study:

  • To review current knowledge on anti-HIV therapy.
  • To discuss the implications of current antiretroviral treatments for patient management.

Main Methods:

  • Review of clinical studies on combination antiretroviral therapy.
  • Analysis of data from clinical endpoint studies involving HIV protease inhibitors.

Related Experiment Videos

Main Results:

  • Combination therapy, particularly with nucleoside analogues, improves survival and delays disease progression in HIV patients.
  • Protease inhibitor-containing regimens show promise for significant viral load reduction and improved survival in advanced HIV infection.

Conclusions:

  • Antiretroviral combinations offer significant hope for improved survival in HIV-infected individuals.
  • Further research is needed to establish optimal treatment initiation, regimen composition, and long-term efficacy for sustained HIV suppression.